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Multiple polymorphisms have shown associations with blood pressure (BP) levels
and hypertension status, but the overall genetic effect on BP has been small and accounts
for only a small fraction of the variation in population-wide BP characteristics. These weak
associations of BP with genotype may not be attributable to the examining the “wrong”
single nucleotide polymorphism (SNP) but may instead be the result of noisy BP phenotypes
based on mmHg alone. Adding information from the underlying mechanisms of nutritional
intake, reuptake, and excretion on BP may produce more informative BP phenotypes to
study.

To explore this complex relationship between diet, genes, and BP we chose 186 BPrelated SNPs from previous genome-wide association studies (GWAS) to test if sodium and
potassium intake modify the existing BP-SNP relationship. Next, we tested if these BPrelated SNPs are associated with sodium and potassium intake. Lastly, we tested if the

effects of sodium and potassium intake on BP are heterogeneous across race/ethnic groups.
We combined data across four cohorts representing 3 racial ancestry groups (Black, White,
and Hispanic participants) from the Population Architecture using Genomics and
Epidemiology (PAGE) consortium to test our hypotheses. All analyses used participant-level
data stratified by cohort and racial ancestry. Model coefficients were combined by metaanalysis and assessed for effect heterogeneity across strata.

We were unable to demonstrate experiment-wide significant interaction effect of
dietary intake on the BP-SNP relationship but the closest nominally significant result
indicated that the CASZ1 gene may play a part in the modulation of BP by both sodium and
potassium among Hispanics. All nominally significant interactions between diet, gene, and
BP showed heterogeneity of effects across racial ancestry groups. As for dietary associations
with BP, we found a higher association between nutritional intake and BP among non-White
participants which support current guideline recommendations of sodium sparing diets
particularly in Black and Hispanic hypertensive patients.

This study has provided more evidence of the heterogeneity of BP phenotypes
among ancestry groups, particularly as they relate to nutritional intake and genetics. While
dietary intake is likely an intermediate phenotype mediating gene-BP relationships, the
effects are small and difficult to detect with highly variable intake measures. We suggest
future studies focus on an alternate subset of SNPs from trans-ancestry BP association

studies and employ a larger sample size in order to demonstrate significant interactions
with dietary intake measures.
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BACKGROUND
Literature Review
Worldwide more than 1 billion adults have hypertension, making it the most
common modifiable risk factor for cardiovascular disease and cardiovascular-related death,
accounting for more than 9 million deaths annually (WHO, 2013). Hypertension occurs more
frequently in populations of African ancestry and is associated with more severe clinical
sequelae and twice the mortality risk compared to populations of European ancestry
(Benjamin et al., 2017). These disparities underscore the fact that hypertension is
etiologically and genetically heterogeneous. The pathophysiologic nature of hypertension is
multifactorial, but primarily driven by renal regulation of urinary excretion of water and
soluble ions (specifically sodium and potassium) to maintain a constant extracellular
environment for proper cell function (Rose & Post, 2001). Multiple genetic loci associated
with blood pressure (BP) levels by genome-wide association studies (GWAS) in populations
of European (Ehret et al., 2011; Levy et al., 2009; Newton-Cheh et al., 2009) and African
ancestry (Fox et al., 2011; Franceschini et al., 2013) are functionally related to the
maintenance of vascular tone and renal regulation of soluble ions (Franceschini et al., 2013)
but causal pathways have yet to be determined for the majority of the GWAS-discovered
BP-related loci.
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Treatments to reduce BP currently consist of a low-sodium diet and/or trial and
error of anti-volume or anti-renin medications. Recently, the evidence of benefit from a low
sodium diet has weakened. In response, the Institute of Medicine (IOM) raised the
recommended sodium intake to <2.3 grams/day for most individuals but kept intake
recommendations at <1.5 grams/day for African-Americans and other higher risk subgroups
(Strom, Anderson, & Ix, 2013). These new racially stratified recommendations are informed
by randomized control trials showing “salt sensitivity”, a precursor of hypertension, to be
more frequent in those of African ancestry. However, the IOM recommendations failed to
discuss that this salt-sensitive hypertension is only present when dietary potassium is
deficient (Adrogué & Madias, 2014; Morris, Sebastian, Forman, Tanaka, & Schmidlin, 1999;
Rodrigues et al., 2014). Further results from a multi-racial, international cohort recently
confirmed the association of high sodium and low potassium intake with higher BP at
baseline but found both low and high sodium intake increased the risk of mortality upon
follow up (Mente et al., 2014; O'Donnell et al., 2014). These recent findings indicate a
paradigm shift in the field of BP that highlight the uncertainty of low sodium diet
recommendations, the importance of potassium as an often-ignored co-factor in BP
regulation, and the racial heterogeneity of environment-influenced BP traits.
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Public Health Significance
While multiple polymorphisms have shown associations with BP levels and
hypertension status, the overall genetic influence on BP has been small and accounts for
only a small fraction of the variation in population-wide BP characteristics. These weak
associations of BP with genotype may not be attributable to the field examining the
“wrong” single nucleotide polymorphism (SNP) but instead be the result of non-specific BP
phenotypes based on mmHg alone. By adding information from the underlying mechanisms
of nutritional intake, reuptake, and excretion on BP, we may be able to create more
informative BP phenotypes. In addition, we know the genetic effect of BP varies by racial
and ethnic ancestry. Only through a large consortium of multiethnic genotypic and
epidemiologic studies like the Population Architecture using Genomics and Epidemiology
(PAGE) consortium can these specific BP phenotypes be studied in large enough numbers to
provide powerful links to established BP genetic markers. Once genetic markers are related
to these precise BP phenotypes, biological pathways of BP dysfunction will be better
elucidated giving practitioners superior tools to control one of the largest contributing
factors to cardiovascular morbidity and mortality worldwide.

Specific Aims
To explore the complex relationship between diet, genes, and BP we first tested if
BP-related SNPs are also associated with sodium and potassium intake. Next, we tested if
3

the effects of sodium and potassium intake on BP are heterogeneous across race/ethnic
groups. Lastly, we tested if sodium and potassium intake modify the existing BP-gene
relationship. We selected SNPs identified as associated with BP or hypertension in the
GWAS catalog (Buniello et al., 2019) before 2017 in European (Bis et al., 2015; Ehret et al.,
2011; Franceschini et al., 2013; Germain et al., 2013; Levy et al., 2009; Newton-Cheh et al.,
2009; Org et al., 2009; Padmanabhan et al., 2010; Salvi et al., 2017; Schneider et al., 2014;
Simino et al., 2014; Turner et al., 2013; Wain et al., 2011), African (Adeyemo et al., 2009; Bis
et al., 2015; Fox et al., 2011; Franceschini et al., 2013; Lettre et al., 2011; Salvi et al., 2017;
Taylor et al., 2016), and Asian (Ehret et al., 2011; Franceschini, Reiner, & Heiss, 2011; He et
al., 2013; Kato et al., 2015; Kato et al., 2011; Kelly et al., 2013; Kim et al., 2014; Leu et al.,
2014; Lu et al., 2015; Newton-Cheh et al., 2009; Simino et al., 2014; Yang et al., 2009)
ancestry studies and stratified all analyses by self-reported ancestry group, testing all
available SNPs in each ancestry group. Findings from this study may elucidate mediation
pathways of BP-related SNPs across race/ethnic groups, define a more specific hypertension
phenotype, and guide effective treatment and prevention of cardiovascular disease.

Specific Aims 1: Test dietary phenotype-gene associations between GWAS-established BPrelated SNPs and sodium and potassium in each race/ethnic group.
i.

Determine if BP-related SNPs are related to sodium and potassium intake from

dietary questionnaires.
4

ii.

Confirm findings of association between BP-related SNPs and sodium and potassium

excretion from a subsample of PAGE studies with 24-hour urine collections.

Specific Aim 2: Estimate the heterogeneity of the effects of sodium and potassium intake
on BP across race/ethnic groups.
i.

Test the extent of effect modification of potassium intake on the relationship

between sodium and BP levels; specifically, if high potassium intake counteracts the effects
of high sodium intake on BP similarly in all race/ethnic groups.
ii.

Determine if the effect of the sodium/potassium ratio on BP is consistent across low

and high sodium intake groups in all race/ethnic groups.

Specific Aim 3: Test the gene-environment interaction of BP-related SNPs with sodium and
potassium intake phenotypes on BP in each race/ethnic group within PAGE.
i.

Test phenotype effect modification of sodium and potassium intake on the

association between established SNPs and BP outcomes in each race/ethnic group.
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METHODS
Study Setting
The PAGE study was initiated by the National Human Genome Research Institute in
2008 to investigate the current epidemiologic knowledge base of well-replicated genetic
variants associated with complex diseases in large, ethnically diverse population-based
studies. PAGE is currently in its third phase of funding from the National Institute of Health
and combines DNA samples and hundreds of phenotypes from the following studies:
Atherosclerosis Risk In Communities (ARIC), Coronary Artery Risk In Young Adults (CARDIA),
Cardiovascular Heart Study (CHS), Hispanic Community Health Study/Study of Latinos (SOL),
The Strong Heart Cohort Study (SHS), The Strong Heart Family Study (SHFS), The Multiethnic
Cohort (MEC), Mount Sinai Medical Center Institute for Personalized Medicine BioMe
Biobank (MSMC), and The Women’s Health Initiative (WHI). This study incorporates
biomarker and genetic data from 4 large studies which includes participants of varying
ethnicity: ARIC (European American and African Americans)("The Atherosclerosis Risk in
Communities (ARIC) Study: design and objectives. The ARIC investigators," 1989), WHI
(Hispanic Americans and African Americans)(Anderson et al., 2003), CARDIA (European
American and African Americans)(Hughes et al., 1987), and SOL (Hispanic
Americans)(Matise et al., 2011; Sorlie et al., 2010).
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Study Subjects
Study participants were included in the analysis if they were genotyped on the
Illumina Metabochip platform or had previously genotyped GWAS data available and
imputed to 1000 Genomes Phase 3. Participants were required to have non-missing systolic
blood pressure (SBP), diastolic blood pressure (DBP), sodium intake, potassium intake, age,
sex, BMI, total protein intake, total caloric intake, serum creatinine, use of anti-hypertensive
medications, and principal component ancestry estimates. Participants were excluded if
dietary caloric intake was outside described thresholds (see Data Analysis section).
Subgroup racial ancestry category was also required for inclusion of participants from the
SOL study.
Data Analysis
The primary phenotypes of interest in this study was BP (systolic and diastolic) and
prevalent hypertension. BP was measured at Visit 1 in ARIC and SOL, Visit 2 in CARDIA, and
observational study Visit 1 in WHI. BP was manually measured in a resting state by a
sphygmomanometer twice in WHI and 3 times in CARDIA and ARIC. Resting BP in SOL was
measured 3 times by automated BP device (OMRON HEM -907XL). The average of the
second and third BP measurements in mmHg were used for CARDIA and ARIC. The average
of all BP measurements in mmHg were used for SOL and WHI. For all studies, SBP was
truncated to a minimum of 30 mmHg and a maximum of 300 mmHg and DBP was truncated
to a minimum of 10 mmHg and a maximum of 150 mmHg. For patients concurrently treated
7

with anti-hypertensive medication, 15 mmHg was added to SBP and 10 mmHg was added to
DBP (Tobin et al., 2005). Hypertension was defined as (unadjusted) BP greater than 140/90
or concurrently taking anti-hypertensive medications.

Dietary intake of sodium, potassium, total calories, and total protein were estimated
by food-frequency questionnaires (ARIC, CARDIA, WHI) and by 24-hour recall (SOL). ARIC
employed an interviewer-administered validated 61-question food-frequency questionnaire
modified from the Willett questionnaire (Willett et al., 1985) to determine dietary intake
patterns over the previous year. CARDIA employed a validated interviewer-administered
food-frequency questionnaire by Burke which was modified from the food-frequency
questionnaire used in the Western Electric Study (McDonald et al., 1991) to determine
dietary intake patterns over the previous month. The SOL study conducted in-person 24hour food recall with random telephone follow-up 24-hour recalls within 6 weeks after inperson interview. Results from a later food propensity questionnaire were used to enhance
the predictive power of the 24-hour recall data. The food propensity questionnaire is similar
to a food-frequency questionnaire but without portion sizes. In the WHI observational
study, the food-frequency questionnaire was designed based on previous WHI studies in
order to assess dietary intake patterns over the previous 3 months and validated using 24
hour recall surveys (Patterson et al., 1999). Dietary intake estimates from WHI and SOL
were determined using the nutrient database from the University of Minnesota Nutrition
8

Coding Center nutrient database (Nutrition Coordinating Center, Minneapolis,
MN)(Patterson et al., 1999; Sorlie et al., 2010). All studies were first analyzed separately in
order to account for differential dietary assessment methods then estimates were metaanalyzed and tested for homogeneity of effects.

Multiple procedures were undertaken in order to standardize dietary intake
measurements. Observations with calories <600 or > 6000 for women and <800 or >8000
for men were removed within CARDIA, WHI, and SOL as this level of caloric intake indicates
inaccurate dietary measurement (Chatterjee et al., 2012; Patterson et al., 1999; Sorensen et
al., 2014). Observations within ARIC were removed if caloric intake was <500 or >3600 for
women and <600 or >4200 for men before being sent to PAGE, thus cutoffs were not
modifiable. While it is known food-frequency questionnaires are prone to underestimation
of sodium intake (Harnack et al., 2017), there is concern that ARIC nutritional data may even
further underestimate true dietary consumption as evidenced in the lower cutoffs
employed for this study. Thus, to control for any bias due to this underestimation in ARIC
dietary data, we conducted a sensitivity analysis excluding ARIC data to confirm any results.
Daily potassium intake (g), sodium intake (g), and protein intake (g) were winsorized at 6
standard deviations to reduce the effect of extreme outliers. BP across quartiles of sodium
and potassium were first examined to assess linearity of effect. Binary categories based on
the median value of sodium intake within study were used to define high vs low sodium and
9

potassium exposure groups. In addition, relationship between BP and sodium:potassium
ratio was examined on a continuous scale.

A total of 186 SNPs that reached genome-wide significance for association with SBP,
DBP, or hypertension in European, African, South Asian, or East Asian populations before
2017 were selected for inclusion from the GWAS catalog (Buniello et al., 2019)– accessed
7/10/2017. All 186 GWAS-established SNPs were required to have shown validated
associations through replication studies. These 186 variants are located in or nearby 162
different gene or gene regions (with 19 of the gene regions represented by 2 or more SNPs).
Of the 186 variants, 9 are non-coding transcript exon variants, 4 are missense, 2 are
synonymous, with the remainder located in introns, flanking, or intergenic regions.
Locations and previous associations of the included variants are in Appendix A. Study
participants were previously genotyped using commercially available genotyping arrays
(Affymetrix 6.0 for ARIC and CARDIA cohorts, MEGAchip for SOL as well as Black and
Hispanic WHI cohorts, and Illumina HumanOmniExpress for White WHI cohort). Genotyped
data was imputed to 1000 Genomes Phase 3 for all studies. Subject level data for replicated
SNPs based on GRCh37 chromosome:position was extracted. A total of 183 replicated SNPs
available from at least one or more PAGE studies were examined in this analysis.
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All analyses were run with individual level data within each study stratified by study
and self-reported ancestry group. Regression models were fit using SUGEN v8.7 which
accounts for family related dependencies (relevant for SOL study only) (Lin et al., 2014).
Baseline SBP and DBP models were fit by linear regression and prevalent hypertension
models were fit by logistic regression (Table 1). Consistent with the original GWAS studies,
additive genetic effects were assumed for all models. Tests of interactions by sodium and
potassium categories with SNPs were made to determine effect modification. To confirm
the adequacy of the linear regression fit we used scatter plots to confirm linearity
assumptions of the model, histograms and QQ plots of residuals to assess normality
assumptions, and scatter plots of predicted values by residuals to determine if any
heteroscedasticity is present. Logistic regression fit was assessed by comparing predicted
versus observed outcomes, and scatter plots of log odds by the continuous covariates were
examined to ensure linearity assumptions of the model are met. Model adequacy was
assessed in models containing all covariates.

Model coefficients were combined by meta-analysis across studies, stratified by selfreported ancestry group. Meta-analysis testing the interaction of genetic by diet effects
across studies were combined using METAL (Willer, Li, & Abecasis, 2010) and a joint 2df test
(Manning et al., 2011; Wu & Becker, 2013). R package “metafor” was used to combine
effects by inverse variance weighted meta-analysis, allowing for random effects by study
11

(Viechtbauer, 2010). After meta-analyzing across studies, heterogeneity of effects across
racial group was tested by inverse variance weighted meta-analysis. Heterogeneity between
study or self-reported ancestry groups were considered significant if I2>75% or Cochran’s Q
p-value<0.05.

Sample Size Calculation
Based on the 183 SNPs available to be tested for significant effect (as outlined in the
specific aims) across 3 ancestry groups (6339 tests), we controlled for Type 1 error with a
Bonferroni corrected significance level of <7.89x10-6. Meta-analyzed coefficients with a
p<0.05 were considered nominally significant. To ensure that we had the power to detect a
gene-environment additive effect of at 3-5 mmHg, we completed an a priori power analysis
for Aim 3 based on an additive genetic model, SBP standard deviation of 20, allele
frequency range 0.2-0.4, desired power of 0.8, and high sodium or low potassium
prevalence of 0.5 using Quanto software (Thomas, 2010). The original power analysis
assumed an experiment-wide Type I Error rate of 7.3x10-5, sample size requirements range
from n=3,188 with 0.5 allele frequency and 5 mmHg gene-environment effect, n=9,462 with
0.4 allele frequency and 3 mmHg gene-environment effect, or at most n=14,323 under the
most constrained condition with 0.2 allele frequency and 3 mmHg gene-environment effect.
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Human Subjects, Animal Subjects, or Safety Considerations
This research study has obtained IRB approval from the UTH CPHS # HSC-SPH-080549 to ensure protections of human subjects. All sites that are part of this consortium have
completed comparable IRB approvals from their respective CPHS committees.
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RESULTS
The PAGE study is made up of multiple diverse studies and participants (Table 2).
Participant data from the earliest study visit where both BP and dietary intake data are
available were included in this dissertation study analysis. Individuals were only included
once to ensure independence of observations. The data collection era varied by study with
ARIC and CARDIA data collected before 1990, WHI between 1994 and 1998 as part of the
observational study component, and SOL most recently from 2009 to 2012. Another
dissimilarity between studies is the age range: ARIC and WHI representing mostly older
participants >40 years, SOL comprising adults ages 18-76 years, and CARDIA representing
only younger adults less than 36 years of age. All studies employed different types of food
frequency questionnaires with the exception of SOL which used a 24-hour food recall to
determine dietary intake. Variability in dietary intake measurements likely results from
differences in methodology as well as from era of the study and age of study participants.
The highest sodium, potassium, and caloric intake were seen in the youngest CARDIA
cohort, and the lowest intakes were seen in the older ARIC cohort. BP also followed a
similar trend with much lower BP and hypertension prevalence (14%) in younger cohorts
and higher BP and hypertension prevalence (30-60%) seen in the older cohorts of ARIC, SOL,
and WHI. Due to the possibility of sodium underestimation in the ARIC cohort, a sensitivity
analysis excluding ARIC participants was completed in additional to the main analysis.
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In evaluating the phenotype-phenotype associations of sodium and potassium
intake on BP, we found no evidence of significant interaction effects between sodium and
potassium on BP outcomes within race/ethnic groups. Moreover, interactions between
sodium:potassium ratio and sodium category did not show significant effects. The closest
nominally significant interaction was observed between sodium:potassium ratio and high
sodium category on DBP in Blacks (β = 1.2, p = 0.049). Specifically, while DBP increased
slightly with sodium:potassium ratio among those with low sodium intake, a markedly
stronger positive association between sodium:potassium ratio and DBP was observed in
participants with the high sodium intake (Figure 1). No other interactions between dietary
intake factors showed significant effect on BP outcomes.
In terms of main effects of dietary intake on BP outcomes, sodium:potassium ratio
did show highly significant positive associations with SBP, DBP, and hypertension among
non-Whites (all p<7.89x10-06, see Table 3). Specifically, for each 1 unit increase in the
sodium:potassium ratio, Blacks showed a 2.1 mmHg rise in SBP and Hispanics showed a 1.4
mmHg increase in SBP, 1.0 mmHg increase in DBP, and a 3% increase in the odds of being
hypertensive. For each of these associations, there was a consistently positive (and
nominally significant effect for SBP and hypertension) across all self-reported ancestry
groups. Of the 14 nominally significant associations, 8 were associated with
sodium:potassium ratio (all higher DBP mmHg, SBP mmHg or hypertension odds with more
15

intake), 5 with potassium (all lower DBP mmHg or hypertension odds with more intake), and
only 1 with sodium intake (higher SBP mmHg with more intake).
In evaluating gene-environment interaction of BP-related SNPs with sodium and
potassium intake on BP, we found no experiment-wide significant interactions between
SNPs and dietary measures (Table 4). All nominally significant interactions are shown in
figures stratified by ancestry group (Figure 2, Figure 3). The most significant SNP-diet
interaction was for the interaction of rs12046278-T (CASZ1) on Chr 1 with both sodium (p
=1.7 x 10-04) and potassium (p =1.3 x 10-04) intake on DBP in Hispanics (Figure 4). Both
interactions similarly affected DBP such that higher sodium intake or higher potassium
intake lessened the SNP-associated increase in DBP seen in participants with low intake.
Another CASZ1 variant rs880315-T showed a similar interaction effect in the same direction
on DBP in Hispanics but with slightly higher p-values (sodium p = 5.4 x 10-04, potassium p =
4.6 x 10-04). Nominally significant interactions were also observed for SBP in Hispanics
between rs12046278-T and sodium (p=1.1 x 10-03) and potassium (p=9.3 x 10-04).
However, while more sodium intake further increased SBP among participants with one or
more T alleles at rs12046278, higher potassium intake lessened the SBP-SNP effect.
Similarly, rs12046278-T also showed a significant interaction with sodium:potassium ratio
on DBP (p=4.6x10-04), indicating increased intake of sodium:potassium increases the
harmful effect of the SNP seen in participants with low sodium intake. CASZ1 variant
rs880315-T showed similar significant interactions between sodium:potassium ratio with
16

DBP in Hispanics (p = 4.6x10-04). No other self-reported ancestry groups saw consistently
significant results at the rs12046278 or rs880315 loci.

There was a potential interaction effect of SV2C associated variant rs6453204-A on
Chr 5 in Whites for DBP with sodium (p = 8.6 x 10-03), potassium (p = 2.7 x 10-03), and the
sodium:potassium ratio (p = 4.2 x 10-03). While the SNP effect from additional A alleles
imparted lower DBP among those with low sodium intake, high sodium intake switched the
direction of the SNP effect to increase DBP. As for the potassium interaction, the more
potassium intake the larger the decrease in DBP associated with the allele. Furthermore,
increases in intake of sodium:potassium ratio attenuated the protective effect from having
one or more A alleles at the rs6453204 locus. Whites also saw similar effects on the odds of
hypertensive in dietary interactions with rs12195230-C (KLHL32) on Chr 6 such that high
sodium intake imparted larger odds of hypertension among participants with the allele (p =
3.9 x 10-03) while high potassium intake reduced the SNP-associated odds of hypertension
compared to participants with low potassium diet (p = 2.5 x 10-03).

In Blacks, 2 loci showed potential interaction effects on DBP between SNPs and all
dietary variables: rs6782531-C (FHIT) on Chr 3 and rs11222084-A (LOC646383) on Chr 11. In
participants with low sodium or low potassium intake, rs6782531-C (Chr 3 FHIT) was
associated with lower DBP. However, high sodium intake attenuated this lower DBP-SNP
17

effect (p = 5.3 x 10-03), high potassium magnified this lower DBP-SNP effect (p = 2.7 x 1003), and thus participants with high sodium:potassium ratio showed an attenuated lowering
DBP-SNP effect (p = 3.4 x 10-04). Dietary intake had a consistent effect on rs11222084 such
that increases in sodium (p = 1.5 x 10-03) or potassium (p = 3.4 x 10-03) both lessened the
overall decrease in DBP associated with additional A alleles at the rs11222084 locus.
However, when considering sodium and potassium together the lower DBP-SNP effect was
magnified in those with increased intake of sodium:potassium ratio (p = 5.6 x 10-04).

Two SNPs were found to be highly associated with dietary intake interactions for SBP
and hypertension in Blacks. Interactions with rs13178964-A (RAB9BP1) on Chr 5 showed
varied association with SBP in Blacks for both sodium (p = 4.2 x 10-03) and potassium (p =
5.3 x 10=03) intake. While the underlying SNP effect imparted decreases in SBP in
participants with low sodium or potassium intake and one or more A alleles, the impact of
increased sodium and potassium intake in this context are opposite from what may be
expected. Specifically, high sodium intake amplified the SNP associated SBP decrease while
high potassium intake attenuated the SNP associated SBP decrease. Similar impact was seen
on the odds of hypertension with dietary interactions with rs6495122 (CPLX3 - ULK3) on Chr
15. High sodium intake increased the odds of hypertension among participants with the
allele and, while the SNP was associated with lower odds of hypertension in participants
with low potassium intake, participants with high potassium showed evidence for an
18

increased odds of hypertension associated with the SNP. Similarly, dietary interactions with
rs16982520 (ZNF831) on Chr 20 also showed this unintuitive effect on the odds of
hypertension in Hispanics: the lower odds of hypertension associated with the SNP was
enhanced in participants with high sodium intake (p = 9.1 x 10-03) but diminished in
participants with high potassium intake (p = 7.7 x 10-03).

Lastly, we investigated possible BP-related SNP associations with dietary intake
measures in hopes of elucidating mechanistic pathways for the established SNP-BP
relationships. No experiment-wide significant findings were found, but nominally significant
associations were found with 63 SNPs (Table 4). The most significant association
demonstrated lower sodium:potassium ratio in Whites with the T allele at rs2014912
(ARHGA24) on Chr 4 (β = -0.01, p = 1.4 x 10-04) (Figure 5). This effect was heterogeneous
across ancestry groups with Blacks having a similar negative T allele effect but Hispanics
with a positive effect (Cochran’s Q = 9.4, p = 8.9 x 10-03).
There were SNPs highly associated with variation in dietary intake. The variant
rs1530440-T (C10orf107) on Chr 10 was associated with lower potassium (β = -57.8, p = 1.1
x 10-03) and higher sodium:potassium ratio (β = 0.03, p = 3.3 x 10-03) in Blacks. Moreover,
two SNPs were associated with lower sodium intake in Blacks: s11891401-A (PRPS1P1) on
Chr 2 (β = -20, p = 1.5 x 10-03) and rs2782980-T (LOC10537) on Chr 10 (β = -17, p = 3.5 x 1003). This same SNP, rs2782980-T, also showed nominally significant interactions with
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dietary intake on BP levels and hypertension status in all race groups, although with
differing effect directions (Table 4). There were 2 different SNPs among Hispanics that
showed association to lower sodium: rs10931896-T (LOC10537) on Chr 2 (β = -29.6, p = 3.7 x
10-03) and rs6015450-A (ZNF831) on Chr 20 (β = -49.9, p = 4.6 x 10-03). Among Whites one
additional SNP, -rs2014912-T (ARHGAP2) on Chr 4, showed high association with decreased
sodium intake (β = -18, p = 2.4 x 10-03). All of these SNPs showed significant heterogeneity
of effects across self-reported ancestry group (Cochrane’s Q p<0.05 for all except rs2014912
and rs2782980 p<0.1). In addition, no apparent associations were seen between the first 5
ancestry principal components and dietary intake variables (Figures 6-8).

Allele frequencies at each locus often varied between self-reported ancestry groups
potentially impacting the power to detect associations between SNPs and outcomes (Figure
2, Figure 3). Specifically, effects related to rs12046278 and rs880315 (both markers of
CASZ1) were only seen in Hispanics who had coded allele frequency (CAF) near 50% while
the CAF in other ancestry groups ranged from 15-35%. Conversely, associations with
rs6453204 on Chr 5 only in Whites were seen despite high CAF (>80%) in all ancestry
groups. Similarly, associations with rs11222084 (LOC646383) were found only among Blacks
while no associations were found in Hispanic or Whites despite common CAF of 20-40% in
all ancestry groups. rs2782980 CAF was common in all ancestry groups and showed
significant dietary interactions with all outcomes in all ancestry groups. In this situation,
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both the power from the CAF and true SNP x diet interaction effect size may both assist in
the detection of a statistically significant association.
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DISCUSSION
In this dissertation, we have shown that dietary intake of sodium and potassium are
highly associated with SBP, DBP, and hypertension particularly in non-Whites across four
separate cohort studies. Moreover, the association between BP and some SNPs have
marginal evidence for potential modulation by sodium and potassium intake. These
interaction effects between diet, gene, and BP were not consistent across racial ancestry
groups, indicating the need for more stratified or advanced analysis techniques that takes
into account ancestral admixture.

The most nominally significant interaction between dietary intake and SNPs affected
DBP in Hispanics. Specifically, this interaction was seen with the T allele of SNP rs12046278,
a marker for gene CASZ1 on chromosome 1. While high intake of both sodium and
potassium decreased the SNP associated rise in DBP, high sodium increased and high
potassium decreased the SNP associated rise in SBP. This SBP relationship with diet is more
what would be expected to occur knowing the general impact shown by potassium lowering
and sodium intake increasing BP. CASZ1 has shown previous association with an increase in
SBP in Europeans with replication among Europeans with additional minor alleles at
rs12046278 (Levy et al., 2009). Recent replication in two female-only European cohorts
observed association with SBP but not with DBP or hypertension (Ho et al., 2011; Won,
Ehret, Chakravarti, & Olshen, 2011). However, no experiment-wide significance with any BP
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phenotypes was found in a recent validation study with an African ancestry cohort (Fox et
al., 2011). No other studies to date have examined this SNP in a Hispanic population. CASZ1
encodes a zinc finger transcription factor potentially related to blood vessel assembly and
morphogenesis (Liu et al., 2014). Liu et al recently developed a knockout mouse model and
determined that CASZ1 is critical to mammalian heart development, specifically relating
CASZ1 to congenital heart disease through decreased cardiomyocyte proliferation.

As for any genetic associations with dietary intake, the closest nominally significant
SNP was rs2014912-T showing increased sodium:potassium ratio in Whites. This SNP is
located in an intron of ARHGAP24 on Chr 4 that has shown previous association with SBP
increase in Euro/Asians by Kato et al (Kato et al., 2015). Mechanistic studies have shown
this intron variant to be related to podocyte formation in the kidney and to the
development of proteinuric kidney diseases in humans as well (Akilesh et al., 2011).
Through the creation of mouse knockdown podocyte cell lines, Akilesh et al showed
ARHGAP24 was highly expressed in podocytes and upregulated as the cells differentiate in
vivo. Earlier work by Ohta et al also confirmed that the highest level of ARHGAP24 transcript
was expressed in the kidney and this GTPase-activating protein for Rac1 specifically
suppresses lamellipodia formation and cell spreading downstream of RhoA signaling which
plays a role in the vasoconstriction characteristic of hypertension (Lee, Webb, & Jin, 2004;
Ohta, Hartwig, & Stossel, 2006). Moreover, Rac1 has been shown to mediate
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mineralocorticoid receptor activation in several animal models of salt-sensitive
hypertension and kidney disease(Nagase & Fujita, 2013).

There was substantial variability of results across ancestry groups with most
significant results detected only in one ancestry group. Despite lack of experiment-wide
significance for the main hypotheses of this study, we have shown important racial
heterogeneity in allele frequency, dietary intake, and BP that should be accounted for in
future studies. While it is known that there are important effects of diet (Benjamin et al.,
2017; Sacks et al., 2001; Strom et al., 2013) and genetic admixture on BP (Franceschini et al.,
2011; Wojcik et al., 2019), a deeper understanding of these effects can only be obtain when
examined in a large sample stratified by race/ancestry group.

In this study, we chose to focus on SNPs previously shown in the literature to be
associated with BP in GWAS studies assuming these SNPs were most likely to show a
significant interaction effect with diet; and such a strategy would improve power by
controlling the number of tests. However, most of these chosen SNPs were only studied and
validated in European and Asian populations. Only 47 SNPs of the 186 chosen were tested
or validated in African ancestry population. Moreover, none of the SNPs had been studied
in Hispanic populations. More recently discovered SNPs in large trans-ancestry analysis may
provide more signal to detect these diet-genetic interaction effects on BP (Giri et al., 2019).
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A recent study by Li et al examined a similar question of urinary sodium excretion
interactions with SNPs affecting BP outcomes(Li et al., 2017). Li et al’s study differed from
the current study primarily due to the subset of chosen SNPs examined as well as
population ancestry (only GENSalt and MESA Asian cohorts) and use of urinary excretion
instead of intake. However, the authors did examine the ARHGAP42 variant rs633185 on
Chr11 showing a significant sodium intake x SNP interaction on pulse pressure. While we did
not examine pulse pressure as an outcome, we did show nominally significant sodium
intake x SNP interaction in Blacks on DBP and hypertension for this variant as well.
Specifically, high sodium intake increased the protective effect of the SNP seen in
participants with low sodium intake.

Urinary sodium and potassium excretion are often more accurate measures of renal
load but were not available for the majority of this study sample. Originally, we had planned
to confirm any significant findings using sodium and potassium excretion in a subset of
patients who underwent 24-hour urine collection analysis. Unfortunately, excretion data
was only available for 485 whites and 558 Blacks from CARDIA, while our most significant
findings were among Hispanics. Moreover, we failed to find any experiment-wide significant
results to confirm. The recent study by Li et al reported significant sodium and SNP
interactions on BP using sodium excretion measures instead of dietary intake measures(Li et
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al., 2017). However, the findings in Li et al are not directly comparable to this study since
our chosen SNPs to investigate did not considerably overlap.

While we failed to find experiment-wide significant results we were able to confirm
the utility of dietary intake data to correlate with BP across multiple large, observational
cohorts, specifically in Black and Hispanic populations using the sodium:potassium ratio
(Table 3). While there are many criticisms of retrospective dietary intake assessment, we
have employed multiple recommended strategies to mitigate the most commonly discussed
issues (Subar et al., 2015). To address systematic underestimation of dietary intake by
nutritional data surveys, we used total energy intake as a covariate in models to improve
the risk estimation of other dietary intake variables. To account for variation between
studies in measurement technique, we employed meta-analysis techniques to first estimate
within study effects and combine effects only if homogenous results. Moreover, to ensure
that underestimation of sodium intake from the ARIC study did not skew results, we
conducted a sensitivity analysis excluding ARIC estimates from the meta-analysis and noted
findings that remained significant. Additional strategies used to ameliorate these issues
included excluding participants with extreme caloric based on each study’s guidelines,
winzorizing continuous dietary intake variables, and dichotomized sodium and potassium by
medians within each study. While the variability of dietary measures may be a major hurdle
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in achieving powerful results in the interaction analysis, they are still useful measures when
carefully employed.

Lastly, in the a priori power analyses we assumed a 3-5mmHg effect from the
interaction between dietary intake and a SNP. However, the actual observed effect size
from the interaction was much smaller; closer to ~1mmHg change in BP due to low or high
intake adjustment to allele effect. This smaller effect size is likely the primary reason for the
lack of experiment-wide significance found in this study. In addition, only a subsample of
SNPs was chosen, many of them not validated in trans-ancestry studies. In the future, an
alternate choice of SNPs with previously demonstrated trans-ancestry effects on BP
analyzed in a larger sample would likely demonstrate significant interactions with dietary
intake measures.
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CONCLUSION
While dietary intake is likely an intermediate phenotype mediating gene-BP
relationships, the effects are small and difficult to detect with highly variable intake
measures. Sodium and potassium excretion measures may provide more precise estimates
but reflect similarly small modulating effects on BP. As of now, no studies have
demonstrated that adding information from the underlying mechanisms of nutritional
intake or excretion on BP actually produces significantly more precise BP phenotypes to
associate with genetic markers. This study does provide more evidence of the heterogeneity
of BP phenotypes among ancestry groups, particularly as they relate to nutritional intake
and genetics. The findings of higher association between nutritional intake and BP among
non-White participants support current guideline recommendations of sodium sparing diets
particularly in Black and Hispanic hypertensive patients. Among Hispanics, the CASZ1 gene
may play a part in the modulation of BP by both sodium and potassium. In order to build on
this work towards elucidating the physiologic pathways between diet, genetics, and BP
future studies should focus on a broader set of SNPs identified through trans-ethnic studies
with large sample sizes that may be able to detect small population level dietary effects on
BP.
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TABLES
Table 1. Model equations
Specific Aim 1
Is sodium or potassium
intake associated with
SNP?
Specific Aim 2
Is BP associated with
sodium, potassium, or
sodium:potassium
ratio?
Is the effect of
sodium:potassium ratio
on BP consistent across
sodium intake?

Specific Aim 3
Is BP-SNP association
modified by sodium,
potassium, or
sodium:potassium
ratio?
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+𝐵𝐵4 𝑆𝑆𝑆𝑆𝑆𝑆 ∗ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 + 𝐵𝐵5 𝑆𝑆𝑆𝑆𝑆𝑆 ∗ 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 + 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝐵𝐵𝐵𝐵 = 𝐵𝐵0 + 𝐵𝐵1 𝑆𝑆𝑆𝑆𝑆𝑆 + 𝐵𝐵2 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠: 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
+ 𝐵𝐵3 𝑆𝑆𝑆𝑆𝑆𝑆 ∗ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠: 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 + 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝐵𝐵𝐵𝐵 = 𝐵𝐵0 + 𝐵𝐵1 𝑆𝑆𝑆𝑆𝑆𝑆 + 𝐵𝐵2 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠: 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
+ 𝐵𝐵3 𝑆𝑆𝑆𝑆𝑆𝑆 ∗ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠: 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 + 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙(𝐻𝐻𝐻𝐻𝐻𝐻) = 𝐵𝐵0 + 𝐵𝐵1 𝑆𝑆𝑆𝑆𝑆𝑆 + 𝐵𝐵2 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠: 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
+ 𝐵𝐵3 𝑆𝑆𝑆𝑆𝑆𝑆 ∗ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠: 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 + 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

SNP: single nucleotide polymorphism, BP: blood pressure, SBP: systolic blood pressure, DBP: diastolic blood
pressure, HTN: hypertension, SA: specific aim
Covariates in all models were sex, age, BMI category, total protein intake, total calorie intake, serum
creatinine, and the first 5 ancestry principal components.
All dietary intake measures were analyzed as continuous variables in SA1. Sodium and potassium intake were
analyzed as binary variables and sodium:potassium ratio was analyzed as a continuous variable in SA2 and
SA3.
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Table 2. Participant characteristics by study cohorts
ARIC
Cohort
15,121
11,747
2,661

CARDIA
Cohort
4,144
2,322
744

9,086
183

1,578
183

Era (Study Visit)

1989 (V1)

1987 (V2)

Median age
Age range
Percent female
Median SBP
SBP range
Median DBP
DBP range
Percent HTN
Median sodium
Sodium range
Median potassium
Potassium range
Median sodium:potassium ratio
Sodium:potassium ratio range

54
44-66
55%
123
61-259
75
10-143
37%
1390.91
210-5214
2506.62
382-9097
0.56
0-2

26
17-36
54%
108
74-166
68
15-111
14%
3153.7
506-14291
3010.7
512-19202
1.06
0-4

Study type
Number with phenotype
Number with phenotype and genotype
Black
Hispanic
White
SNPs available

SOL
Cohort
11,516
11,449
11,449*
180
2009-2012
(V1)
47
18-76
59%
122
74-246
74
40-134
30%
2946.0145
47-21761
2351.056
155-14472
1.29
0-9

WHI
Cohort
46,188
14,107
5,228*
3,378*
5,501
184
1994-1998
(OS V1)
65
49-81
100%
134
80-235
80
40-125
60%
2472.295
343-11638
2346.974
325-9384
1.08
0-3

*All genotypes imputed to 1000 Genomes Phase 3 from GWAS files except SOL and Black and Hispanic WHI
genotypes imputed to 1000 Genomes Phase 3 from Illumina Metabochip.
Note: race, age, sex, SBP, DBP, hypertension, sodium, potassium, and sodium:potassium ratio statistics are
within the sample of participants with all phenotype and genotype data available.
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Table 3. Blood pressure phenotype associations to dietary intake measures in each racial
ancestry group (Specific Aim 2)
Outcome

Race

NObs

NStudies

Factor

Beta

SE

p-value

I2

Q Hetero
Statisitc

Q Hetero
p-value

SBP*

Black

13829

3

POT

-0.975

0.402

1.541E-02

0.000

0.469

7.909E-01

SBP*

Hispanic

14919

2

POT

-1.271

0.348

2.634E-04

0.000

0.013

9.082E-01

SBP

White

24832

3

POT

-0.212

0.278

4.440E-01

0.000

0.343

8.425E-01

SBP

Black

13829

3

SOD

-0.053

0.438

9.032E-01

0.000

0.519

7.716E-01

SBP

Hispanic

14919

2

SOD

0.446

0.353

2.067E-01

0.000

2.051

1.521E-01

SBP

White

24832

3

SOD

0.044

0.335

8.957E-01

0.000

0.188

9.105E-01

SBP*

Black

13829

3

SODPOTRATIO

2.090

0.434

1.488E-06

0.000

2.021

3.640E-01

SBP*

Hispanic

14919

2

SODPOTRATIO

1.395

0.212

4.669E-11

0.000

0.833

3.614E-01

SBP*

White

24833

3

SODPOTRATIO

1.118

0.446

1.219E-02

0.001

2.182

3.359E-01

DBP

Black

13829

3

POT

-0.395

0.326

2.248E-01

27.401

4.022

1.339E-01

DBP*

Hispanic

14919

2

POT

-0.556

0.222

1.214E-02

0.000

0.430

5.119E-01

DBP

White

24832

3

POT

-0.239

0.172

1.663E-01

0.004

2.619

2.699E-01

DBP

Black

13829

3

SOD

-0.378

0.284

1.827E-01

0.000

1.380

5.017E-01

DBP*

Hispanic

14919

2

SOD

0.496

0.225

2.748E-02

0.001

1.270

2.597E-01

DBP

White

24832

3

SOD

-0.357

0.308

2.471E-01

44.318

5.419

6.658E-02

DBP

Black

13829

3

SODPOTRATIO

1.284

0.901

1.541E-01

83.008

14.443

7.308E-04

DBP*

Hispanic

14919

2

SODPOTRATIO

0.950

0.137

4.274E-12

0.000

0.297

5.856E-01

DBP*

White

24833

3

SODPOTRATIO

0.815

0.284

4.097E-03

0.001

2.532

2.820E-01

HTN*

Black

13829

3

POT

-0.023

0.010

2.195E-02

0.067

2.460

2.923E-01

HTN*

Hispanic

14919

2

POT

-0.017

0.009

4.671E-02

0.000

0.490

4.841E-01

HTN

White

24832

3

POT

-0.012

0.007

1.016E-01

0.000

0.395

8.208E-01

HTN

Black

13829

3

SOD

0.021

0.015

1.587E-01

26.288

4.159

1.250E-01

HTN

Hispanic

14919

2

SOD

0.012

0.013

3.676E-01

31.052

3.730

5.346E-02

HTN

White

24832

3

SOD

-0.002

0.009

8.325E-01

0.000

1.643

4.397E-01

HTN*

Black

13829

3

SODPOTRATIO

0.041

0.011

2.495E-04

0.000

1.696

4.282E-01

HTN*

Hispanic

14919

2

SODPOTRATIO

0.025

0.005

1.904E-06

0.028

2.248

1.338E-01

HTN*

White

24833

3

SODPOTRATIO

0.036

0.014

9.014E-03

16.331

3.355

1.868E-01

* nominal significance, p<0.05
* experiment-wide significance, p<7.89x10-06
SBP: systolic blood pressure, DBP: diastolic blood pressure, HTN: hypertension, SOD: sodium, POT: potassium,
SODPOTRATIO: sodium-to-potassium ratio
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which
studies
WHI ARIC
CARDIA
WHI SOL
WHI ARIC
CARDIA
WHI ARIC
CARDIA
WHI SOL
WHI ARIC
CARDIA
WHI ARIC
CARDIA
WHI SOL
WHI ARIC
CARDIA
WHI ARIC
CARDIA
WHI SOL
WHI ARIC
CARDIA
WHI ARIC
CARDIA
WHI SOL
WHI ARIC
CARDIA
WHI ARIC
CARDIA
WHI SOL
WHI ARIC
CARDIA
WHI ARIC
CARDIA
WHI SOL
WHI ARIC
CARDIA
WHI ARIC
CARDIA
WHI SOL
WHI ARIC
CARDIA
WHI ARIC
CARDIA
WHI SOL
WHI ARIC
CARDIA

Table 4. Summary of nominal SNP associations with dietary intake (Specific Aim 1) and
nominal BP associations with dietary intake and SNP interaction (Specific Aim 3)
Mapped
Gene
CAPZA1

SNP
rs10745332

Chr
1

rs17030613

1

CAPZA1

rs12046278

1

CASZ1

rs880315

1

CASZ1

Nominal
Dietary Intake
Association*

SOD(Black-)

POT(Black-)

Nominal BP Association with
Dietary Intake x SNP Interaction
HTN~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less protective SNP
effect than low intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less harmful SNP
effect than low intake)
SBP~SODxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
DBP~SODxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
HTN~SODxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
SBP~SODxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
DBP~SODxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
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Previous
SNP Effect
in GWAS†
harmful
harmful/
protective
protective

harmful

DBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)

rs4077408

1

HHAT

rs1330225

1

rs309064

1

LOC1269
87 LOC1053
78887
LPPR5

rs17367504

1

MTHFR

rs3768939

2

AGAP1

rs4665630

2

KLHL29

rs825937

2

LINC012
49 RNU6-

POT(Black+)

POT(Black-)

SBP~SODxSNP (White, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~POTxSNP (White, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
HTN~SODPOTRATIOxSNP (Black,
Quantitative: High intake more harmful SNP
effect than low intake)

harmful

HTN~SODPOTRATIOxSNP (White,
Quantitative: High intake more protective
SNP effect than low intake)

harmful

SBP~SODxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more protective
SNP effect than low intake)
DBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more protective
SNP effect than low intake)
SBP~SODxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (White,
Quantitative: High intake more protective
SNP effect than low intake)
HTN~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more protective
SNP effect than low intake)

protective
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protective

protective

harmful

649P
rs7604423

2

LOC1005
06047

POT(Black-)

protective

SODPOTRATIO(Black+)

rs7565329

2

LOC1019
27701 LOC4020
76

rs897876

2

LOC1053
69166

POT(White-)

rs10931896

2

LOC1053
73833 SPATS2L

SOD(Hispanic-)
SODPOTRATIO(Hispanic-)

rs7577262

2

MSL3P1 TRPM8

POT(Black+)

SBP~SODxSNP (Hispanic, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODxSNP (Hispanic, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (White, Qualitative:
High intake switches to harmful SNP effect
from protective in low intake)
SBP~SODxSNP (Black, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
SBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less protective SNP
effect than low intake)

protective

DBP~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~POTxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODxSNP (Hispanic, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake),
SBP~POTxSNP (Hispanic, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
SBP~SODPOTRATIOxSNP (Hispanic,

harmful

harmful
harmful

protective

SODPOTRATIO(Black-)

rs11891401

2

PRPS1P1
CYP2C56
P

SOD(Black-)

rs4638749

2

SULT1C3
WASF1P
1

SODPOTRATIO(Black+)

rs13067306

3

ARMC10
P1 LOC1053
73992

34

protective

harmful

Qualitative: High intake switches to harmful
SNP effect from protective in low intake)
rs9810888

3

CACNA1
D

rs6782531

3

FHIT

rs319690

3

MAP4

rs419076

3

MECOM

POT(Black+)

SBP~SODxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
SBP~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less protective SNP
effect than low intake)
DBP~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less protective SNP
effect than low intake)
DBP~SODxSNP (Black, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
DBP~POTxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake), NA,
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less protective SNP
effect than low intake)
DBP~SODxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
DBP~POTxSNP (Black, Quantitative: High
intake less harmful SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (White,
Quantitative: High intake less protective SNP
effect than low intake)
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harmful

protective

harmful

harmful

rs448378

3

MECOM

POT(Black-)

rs1918974

3

MECOM,
LOC1053
74205

SOD(Black-)

rs13082711

3

SOD(Hispanic+)

rs820430

3

UBA52P4
LOC1053
77005
UBA52P4
LOC1053
77005

rs3774372

3

ULK4

rs9815354

3

ULK4

rs2014912

4

ARHGAP
24

rs13143871

4

GUCY1A
3

rs13139571

4

GUCY1A
3,

SODPOTRATIO(Black+)

SOD(White-)
SODPOTRATIO(White-)

SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less harmful SNP
effect than low intake)
DBP~SODxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~POTxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (White,
Quantitative: High intake less harmful SNP
effect than low intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less harmful SNP
effect than low intake)
HTN~POTxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)

protective

SBP~POTxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (White,
Quantitative: High intake more protective
SNP effect than low intake)
SBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake more protective
SNP effect than low intake)
SBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake more harmful SNP
effect than low intake)
SBP~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less protective SNP
effect than low intake)
DBP~SODxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake),
DBP~SODxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low

harmful
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protective

protective

harmful
harmful
harmful

harmful
harmful

LOC1079
84032
rs871606

4

LOC1001
29728 RPL21P4
4

rs991316

4

LOC1027
23576

rs12642634

4

LOC1053
77468 LOC1053
77469

rs11099098

4

PRDM8 FGF5

rs1458038

4

PRDM8 FGF5

rs16998073

4

PRDM8 FGF5

SOD(Black+)

POT(Black+
hispanic+)
SODPOTRATIO(Black-)

intake)
HTN~SODxSNP (White, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
HTN~SODxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~POTxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (White,
Qualitative: High intake switches to harmful
SNP effect from protective in low intake)
HTN~SODPOTRATIOxSNP (White,
Quantitative: High intake less harmful SNP
effect than low intake)
HTN~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~POTxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (Black, Qualitative:
High intake switches to protective SNP effect
from harmful in low intake)
DBP~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake more protective
SNP effect than low intake)
HTN~SODPOTRATIOxSNP (White,
Qualitative: High intake switches to harmful
SNP effect from protective in low intake)
DBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake more protective
SNP effect than low intake)
HTN~SODPOTRATIOxSNP (White,
Qualitative: High intake switches to harmful
SNP effect from protective in low intake)
HTN~SODPOTRATIOxSNP (White,
Qualitative: High intake switches to
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harmful

harmful

harmful

harmful

harmful

rs1902859

4

PRDM8 FGF5

rs13107325

4

SLC39A8

rs6825911

4

ZNF969P
- ENPEP

rs9313772

5

LOC1019
27697

rs13178964

5

LOC1053
79111 RAB9BP1

POT(Black-)

NPR3

SOD(Black-)

rs1421811

5

SOD(Hispanic-)

SODPOTRATIO(Black+)

protective SNP effect from harmful in low
intake)
DBP~POTxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less harmful SNP
effect than low intake)
HTN~SODPOTRATIOxSNP (White,
Qualitative: High intake switches to
protective SNP effect from harmful in low
intake)
HTN~SODxSNP (Hispanic, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
HTN~POTxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Qualitative: High intake switches to
protective SNP effect from harmful in low
intake)
DBP~SODxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Hispanic,
Qualitative: High intake switches to
protective SNP effect from harmful in low
intake)
DBP~SODxSNP (Black, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
DBP~POTxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less harmful SNP
effect than low intake)
SBP~SODxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~POTxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Black, Qualitative:
High intake switches to protective SNP effect
from harmful in low intake)
38

harmful

protective

harmful

protective

protective

protective

rs822127

5

PLCXD3 TCP1P2

rs9687065

5

SH3TC2

SOD(White-)

rs6453204

5

SV2C

POT(Black+)

rs9370524

6

COL21A1

rs1799945

6

HFE

SOD(Hispanic+)

rs198846

6

SOD(Hispanic-)

rs12195230

6

HIST1H4
CHIST1H1
T
KLHL32

rs6924906

6

LOC1053
77871

rs13209747

6

LOC1053
77992 LOC1053
77989

rs12195036

6

LOC1053
78117

HTN~SODPOTRATIOxSNP (White,
Qualitative: High intake switches to harmful
SNP effect from protective in low intake)
DBP~SODxSNP (White, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
DBP~POTxSNP (White, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (White,
Quantitative: High intake less protective SNP
effect than low intake)
DBP~SODxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)

protective
harmful

harmful
harmful
protective

DBP~SODxSNP (Hispanic, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
HTN~SODxSNP (White, Quantitative: High
intake more harmful SNP effect than low
intake)
HTN~POTxSNP (White, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
SBP~SODxSNP (Black, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
SBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less protective SNP
effect than low intake)
SBP~SODPOTRATIOxSNP (White, Qualitative:
High intake switches to harmful SNP effect
from protective in low intake)
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harmful

protective

harmful

protective

rs675026

6

OPRM1

rs17080102

6

PLEKHG1

SOD(White-)

rs11750990

6

RNU2-8P
SLC25A5
P7

SOD(Black+)

rs2021783

6

TNXB

rs17477177

7

rs17428471

7

LOC1027
24339 RNA5SP2
36
RPL35P4
LOC1079
86733

rs7801190

7

SLC12A9

rs12541063

8

LOC1019
27845

rs10504249

8

LOC1053
75856

rs2627282

8

LOC1053
77787,
LOC1053
77786

POT(White-)

SOD(White+)
SODPOTRATIO(White+)

HTN~SODPOTRATIOxSNP (White,
Quantitative: High intake more harmful SNP
effect than low intake)
HTN~SODxSNP (Black, Quantitative: High
intake less harmful SNP effect than low
intake)
HTN~POTxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (Black,
Quantitative: High intake more harmful SNP
effect than low intake)

protective

DBP~SODxSNP (Black, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
DBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less protective SNP
effect than low intake)

harmful

HTN~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (Black,
Quantitative: High intake less protective SNP
effect than low intake)
HTN~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less harmful SNP
effect than low intake)
HTN~SODPOTRATIOxSNP (Hispanic,
Qualitative: High intake switches to harmful
SNP effect from protective in low intake)
SBP~POTxSNP (White, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (White,
Quantitative: High intake less protective SNP
effect than low intake)
HTN~SODxSNP (Black, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)

harmful
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harmful
protective

protective
harmful

protective

rs11775334

8

MSRA

rs2198596

8

SGCZ

rs3118867

9

DAPK1

rs17755650

9

LOC1079
87026 MTAP

SOD(White-)

rs1530440

10

C10orf10
7

POT(Black-)

C10orf10
7
C10orf32
-ASMT

SOD(White+)

C10orf32
-ASMT,
C10orf32

SODPOTRATIO(Hispanic+)

rs4590817

10

rs12416687

10

rs4409766

10

POT(Black-)
SOD(Hispanic-)
SODPOTRATIO(Hispanic-)

SODPOTRATIO(Black+)

HTN~SODxSNP (Black, Quantitative: High
intake less harmful SNP effect than low
intake)
HTN~POTxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (Black,
Quantitative: High intake less harmful SNP
effect than low intake)

harmful

SBP~POTxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake more harmful SNP
effect than low intake)
DBP~SODPOTRATIOxSNP (White,
Quantitative: High intake more protective
SNP effect than low intake)
HTN~SODxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~POTxSNP (White, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less harmful SNP
effect than low intake)
DBP~SODPOTRATIOxSNP (White,
Quantitative: High intake less harmful SNP
effect than low intake)
HTN~SODPOTRATIOxSNP (Black, Qualitative:
High intake switches to protective SNP effect
from harmful in low intake)

protective

HTN~SODPOTRATIOxSNP (White,
Quantitative: High intake less harmful SNP
effect than low intake)
SBP~POTxSNP (Black, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Hispanic,

protective
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protective

harmful

protective

harmful

harmful

Quantitative: High intake more protective
SNP effect than low intake)
rs11014166

10

CACNB2

SODPOTRATIO(Black-)

rs11191548

10

CNNM2

SODPOTRATIO(Hispanic+)

rs1004467

10

CYP17A1

SODPOTRATIO(Hispanic+)

rs3824755

10

CYP17A1

SODPOTRATIO(Hispanic-)

rs7088591

10

LOC1053
78314 MRPS35
P3

harmful
SBP~POTxSNP (Black, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
SBP~SODxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
SBP~POTxSNP (Black, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more protective
SNP effect than low intake)
SBP~POTxSNP (Black, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
DBP~SODxSNP (White, Quantitative: High
intake less harmful SNP effect than low
intake)
DBP~POTxSNP (White, Quantitative: High
intake less harmful SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (White,
Quantitative: High intake less harmful SNP
effect than low intake)
HTN~SODPOTRATIOxSNP (White,
Qualitative: High intake switches to
protective SNP effect from harmful in low
intake)
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harmful
harmful

protective

protective

rs2782980

10

LOC1053
78492

SOD(Black-)

rs11191593

10

NT5C2

SODPOTRATIO(Hispanic+)

rs932764

10

PLCE1

POT(White+)

rs9663362

10

PLCE1

POT(White-)

SBP~POTxSNP (Black, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
SBP~SODxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
DBP~SODxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
HTN~SODxSNP (White, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
HTN~POTxSNP (White, Quantitative: High
intake more harmful SNP effect than low
intake)
SBP~SODxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
SBP~POTxSNP (Black, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
HTN~POTxSNP (Black, Quantitative: High
intake less harmful SNP effect than low
intake)
HTN~SODxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
HTN~POTxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
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protective

harmful

harmful

protective

rs4373814

10

SLC39A1
2CACNB2

rs633185

11

ARHGAP
42

rs7129220

11

POT(Black-)

rs1943466

11

CAND1.1
1
GRAMD1
B

rs10832417

11

KCNQ1O
T1,
KCNQ1

SOD(White-)

SBP~SODxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more protective
SNP effect than low intake)
DBP~SODxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~SODxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
HTN~SODxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less protective SNP
effect than low intake)
SBP~SODxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more protective
SNP effect than low intake)
DBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
HTN~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (Black,
Quantitative: High intake less protective SNP
effect than low intake)
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protective

harmful/p
rotective

protective

protective

rs11222084

11

LOC6463
83

rs2196122

11

OR51H1
OR51H2P

rs11024074

11

PLEKHA7

rs4757391

11

SOX6

rs17249754

12

ATP2B1

rs2681492

12

ATP2B1

SODPOTRATIO(Hispanic-)

SBP~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Black, Qualitative:
High intake switches to protective SNP effect
from harmful in low intake)
DBP~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~POTxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake more protective
SNP effect than low intake)
HTN~SODxSNP (Hispanic, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
HTN~POTxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less harmful SNP
effect than low intake)

harmful

SBP~SODxSNP (Hispanic, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less harmful SNP
effect than low intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
DBP~SODxSNP (Hispanic, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
HTN~SODPOTRATIOxSNP (Black, Qualitative:
High intake switches to harmful SNP effect
from protective in low intake)
HTN~POTxSNP (White, Quantitative: High
intake more protective SNP effect than low

harmful
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harmful

protective

harmful/p
rotective

harmful

intake)
rs11066280

12

HECTD4

SODPOTRATIO(Hispanic-)

rs12579720

12

LOC1005
06393

rs35444

12

rs11067763

12

LOC1027
23639 LOC1053
70003
LOC1053
70003

rs7960884

12

OVOS2 LOC1079
87168

rs4842666

12

POC1B ATP2B1

rs2315885

13

SODPOTRATIO(Black+)

rs8002688

13

MIR5007
HNF4GP
1
PIBF1

rs11158609

14

POT(White+)
SOD(Hispanic+)

rs10143078

14

NEDD8,
NEDD8MDP1
SYNJ2BP

DBP~POTxSNP (White, Quantitative: High
intake more harmful SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (White,
Quantitative: High intake less harmful SNP
effect than low intake)
SBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
SOD(White+)

SOD(White+)

harmful/p
rotective
protective

harmful

DBP~SODxSNP (Black, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
DBP~POTxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less protective SNP
effect than low intake)
SBP~SODxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~POTxSNP (Black, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
HTN~POTxSNP (White, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)

harmful

DBP~SODxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)

harmful

DBP~SODPOTRATIOxSNP (Hispanic,

protective
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harmful

harmful

harmful

SYNJ2BPCOX16
rs177848

14

TTC6

rs6495122

15

CPLX3 ULK3

rs1378942

15

CSK

rs1550576

15

LOC1079
84724 ALDH1A2

rs16962897

16

DNAAF1

rs1862746

16

LOC1019
27605

rs2030114

16

LOC1027
23323 LOC1079
84892

rs4150161

16

TAF1C

SOD(White-)

Qualitative: High intake switches to
protective SNP effect from harmful in low
intake)
SBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake less protective SNP
effect than low intake)
DBP~SODxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
HTN~SODxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
HTN~POTxSNP (Black, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
HTN~SODxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
HTN~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
HTN~SODxSNP (White, Quantitative: High
intake less harmful SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (Black,
Quantitative: High intake more harmful SNP
effect than low intake)
HTN~SODxSNP (Hispanic, Quantitative: High
intake less harmful SNP effect than low
intake)
HTN~POTxSNP (Hispanic, Quantitative: High
intake more harmful SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
HTN~SODxSNP (Black, Quantitative: High
intake more harmful SNP effect than low
intake)
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protective

harmful

harmful/p
rotective

protective

protective

harmful

rs17608766

17

GOSR2

rs16948048

17

LOC1027
24596

rs747685

17

NXN

SODPOTRATIO(White+)

rs747687

17

NXN

SODPOTRATIO(White+)

rs12946454

17

PLCD3

rs8065772

17

PRKCA CACNG5

SODPOTRATIO(White+)

rs8078051

17

TTYH2

POT(Black-)

SBP~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~SODxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~POTxSNP (Black, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODxSNP (Hispanic, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)

protective

harmful
harmful
harmful

SBP~SODxSNP (Black, Qualitative: High
intake switches to harmful SNP effect from
protective in low intake)
SBP~POTxSNP (Black, Quantitative: High
intake more protective SNP effect than low
intake)
SBP~SODxSNP (White, Quantitative: High
intake less harmful SNP effect than low
intake)
SBP~POTxSNP (White, Quantitative: High
intake less harmful SNP effect than low
intake)
, NASBP~SODxSNP (White, Quantitative:
High intake more harmful SNP effect than
low intake)
SBP~POTxSNP (White, Quantitative: High
intake less harmful SNP effect than low
intake)

harmful

SODPOTRATIO(Black+)
rs2217560

18

rs7233332

18

LOC1053
72189 CBLN2
RAB31

SOD(White+)
POT(White-)

HTN~SODPOTRATIOxSNP (White,
Quantitative: High intake more harmful SNP
effect than low intake)
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harmful

rs16964543

19

ZNF536

rs2273359

20

NELFCD

SOD(White+)

rs16982520

20

ZNF831

SOD(Hispanic-)

rs6015450

20

ZNF831

SOD(Hispanic-)
SODPOTRATIO(Hispanic-)

SBP~SODxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake less protective SNP
effect than low intake)
HTN~SODxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more protective
SNP effect than low intake)

protective

SBP~SODxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
HTN~SODxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
HTN~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~SODxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low

protective
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harmful

harmful

intake)
HTN~SODxSNP (Hispanic, Quantitative: High
intake more protective SNP effect than low
intake)
HTN~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake)
rs1735151

21

IGSF5

POT(Black+)
SODPOTRATIO(Hispanic+)

rs1475591

21

UBE3AP2
- TIAM1

SOD(Black-)
SODPOTRATIO(Black-)

rs7286472

22

SOD(Black+)

rs130318

22

LARGE LOC1053
73010
PARVB

SODPOTRATIO(Hispanic+)

SBP~SODxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~POTxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
SBP~SODPOTRATIOxSNP (White,
Quantitative: High intake more protective
SNP effect than low intake)
DBP~SODxSNP (White, Quantitative: High
intake less protective SNP effect than low
intake)
DBP~POTxSNP (White, Quantitative: High
intake more protective SNP effect than low
intake)
DBP~SODPOTRATIOxSNP (White,
Quantitative: High intake more protective
SNP effect than low intake)
DBP~SODPOTRATIOxSNP (Hispanic,
Quantitative: High intake more harmful SNP
effect than low intake)
HTN~POTxSNP (Black, Qualitative: High
intake switches to protective SNP effect
from harmful in low intake)
HTN~POTxSNP (Hispanic, Quantitative: High
intake less protective SNP effect than low
intake),

protective

SNP: single nucleotide polymorphism identifier based on Human Genome Assembly GRCh37, Chr: chromosome, BP:
blood pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure, HTN: hypertension, SOD: sodium, POT:
potassium, SODPOTRATIO: sodium-to-potassium ratio
*Association between dietary intake and SNP only listed when nominally significant with ancestry group and direction
of effect, increased (+) or decreased (+) intake with each additional coded allele, noted in parentheses.
†Harmful effect defined as increase in SBP, DBP, or odds of hypertension with each additional coded allele; protective
effect defined as decrease in SBP, DBP, or odds of hypertension with each additional coded allele.
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FIGURES
Figure 1. DBP association with sodium:potassium ratio at low and high sodium intake levels
in Blacks (Specific Aim 2)
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Figure 2. Interaction effects between SNPs and sodium or potassium intake on BP
phenotypes (Specific Aim 3)

52

Figure 3. Interaction effects between SNPs and sodium:potassium ratio on BP phenotypes
(Specific Aim 3)
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Figure 4. Manhattan plots of interaction effects between SNPs and dietary intake on DBP
(Specific Aim 3)
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Figure 5. Manhattan plots of SNPs effects on dietary intake (Specific Aim 1)
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Figure 6. Evaluation of principal component association with sodium intake
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Figure 7. Evaluation of principal component association with potassium intake
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Figure 8. Evaluation of principal component association with sodium:potassium ratio intake
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APPENDICES
Appendix A: Location and previous association of 186 chosen SNPs related to SBP, DBP, or
hypertension identified from previous GWAS
Mapped
Gene
CAPZA1

Disease Trait
SBP, DBP, HTN

1

CAPZA1

BP

rs2932538

1

CAPZA1 MOV10

HTN, SBP

rs12046278

1

CASZ1

SBP

rs880315

1

CASZ1

SBP, DBP

rs4077408

1

HHAT

HTN

rs1330225

1

SBP, DBP

rs309064

1

LOC126987
LOC105378
887
LPPR5

rs17367504

1

MTHFR

DBP, HTN

rs7526425

1

HTN

rs3768939

2

RD3 LOC107985
261
AGAP1

rs11693319

2

CCDC141

BP

rs13002573

2

FIGN PRPS1P1

BP

rs1446468

2

FIGN PRPS1P1

BP

rs16849225

2

FIGN -

BP

SNP
rs10745332

Chr
1

rs17030613

BP

HTN

Effect
[0.61-1.31]
unit increase
[0.27-0.71]
mm Hg
increase
[0.14-0.36]
mmHg
increase
[0.29-0.77]
mm Hg
decrease
[0.38-0.74]
mm Hg
increase
0.25 unit
increase
[3.60-7.36]
mmHg
decrease

Interpretation
harmful

Publication
Lu X, 2015

harmful;
protective

Kato N, 2011; Kato N,
2015

harmful

Wain LV, 2011; Ehret
GB, 2011

protective

Levy D, 2009

harmful

Kato N, 2011, Lu X,
2015

harmful

Bis JC, 2015

protective

He J, 2013

[0.11-0.27]
unit increase
[0.63-1.07]
mm Hg
decrease
[1.09-1.24]

harmful

Kim YK, 2014

protective

Newton-Cheh C, 2009;
Wain LV, 2011

NA

Lettre G, 2011

0.35 unit
decrease
[2.94-6.50]
mmHg
decrease
[0.20-0.42]
mmHg
decrease
[0.24-0.44]
mmHg
decrease
[0.53-0.97]

protective

Bis JC, 2015

protective

He J, 2013

protective

Wain LV, 2011

protective

Wain LV, 2011

harmful;

Kato N, 2011; Kato N,
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PRPS1P1

mm Hg
increase
[1.13-1.3]

protective

2015

NA

Lettre G, 2011

[0.52-1.14]
mmHg
increase
[0.14-0.28]
mmHg
decrease
1.7 mm Hg
decrease

harmful

Simino J, 2014

protective

Kato N, 2015

protective

Salvi E, 2017

[0.45-1.62]
unit increase
[0.37-0.81]
unit increase

harmful

Leu HB, 2014

harmful

Kim YK, 2014

DBP, HTN

[2.06-4.34]
mmHg
decrease

protective

He J, 2013

SBP

[0.16-0.37]
mmHg
increase
[0.61-1.39]
mmHg
decrease
[0.4-0.94]
mmHg
increase
[2.14-4.42]
mmHg
decrease
[1.2-2.6] mm
Hg increase
in DBP
[0.5-1.12]
mmHg
decrease
[2.98-6.74]
mmHg
increase

harmful

Kato N, 2015

protective

He J, 2013

harmful

Simino J, 2014

protective

He J, 2013

harmful

Wang Y, 2008

protective

Simino J, 2014

harmful

He J, 2013

[0.33-0.73]
unit increase
[0.58-1.36]
mmHg
decrease

harmful

Lu X, 2015

protective

Simino J, 2014

rs4665630

2

KLHL29

HTN

rs825937

2

BP

rs7604423

2

LINC01249
- RNU6649P
LOC100506
047

rs7565329

2

SBP

rs897876

2

rs13390641

2

rs10930597

2

rs10931896

2

rs7577262

2

LOC101927
701 LOC402076
LOC105369
166
LOC105373
519 LOC728815
LOC105373
744 LOC100131
562
LOC105373
833 SPATS2L
MSL3P1 TRPM8

rs11891401

2

PRPS1P1 CYP2C56P

BP

rs11887188

2

BP

rs6749447

2

RPS20P12 LOC105373
934
STK39

rs4638749

2

SULT1C3 WASF1P1

BP

rs13067306

3

BP

rs9810888

3

ARMC10P1
LOC105373
992
CACNA1D

rs6782531

3

FHIT

BP

DBP

BP
BP

BP

BP

SBP, DBP, HTN

60

rs16833934

3

BP

[1.06-2.2]
mmHg
decrease

protective

Simino J, 2014

3

LOC730129
LOC102724
419
MAP4

rs319690

BP

harmful

Wain LV, 2011

rs419076

3

MECOM

BP, SBP, DBP

harmful

Wain LV, 2011; Ehret
GB, 2011

rs448378

3

MECOM

SBP

protective

Levy D, 2009

rs1918974

3

DBP

protective

Newton-Cheh C, 2009

rs13082711

3

protective

Wain LV, 2011; Ehret
GB, 2011

rs820430

3

harmful

Lu X, 2015

rs1717027

3

MECOM,
LOC105374
205
UBA52P4 LOC105377
005
UBA52P4 LOC105377
005
ULK4

[0.20-0.40]
mmHg
increase
[0.25-0.43]
mmHg
increase
[0.31-0.71]
mm Hg
decrease
[0.17-0.37]
mm Hg
decrease
[0.22-0.45]
mmHg
decrease
[0.54-0.98]
unit increase

harmful

Franceschini N, 2013

rs3774372

3

ULK4

BP

harmful

Wain LV, 2011

rs9815354

3

ULK4

DBP

harmful

Levy D, 2009

rs2014912

4

ARHGAP24

SBP

harmful

Kato N, 2015

rs13143871

4

GUCY1A3

SBP,DBP,HTN

harmful

Lu X, 2015

rs13139571

4

BP, SBP, DBP,
HTN

harmful

Wain LV, 2011; Ehret
GB, 2011, Lu X 2015

rs871606

4

harmful

Wain LV, 2011

rs991316

4

HTN

NA

Adeyemo A, 2009

rs17589290

4

HTN

[1.22-1.67]

NA

Lettre G, 2011

rs10026364

4

GUCY1A3,
LOC107984
032
LOC100129
728 RPL21P44
LOC102723
576
LOC105377
369 CCDC34P1
LOC105377
436

[0.29-0.69]
unit increase
[0.18-0.42]
mmHg
increase
[0.33-0.65]
mm Hg
increase
[0.48-0.76]
mmHg
increase
[0.61-1.88]
unit increase
[0.18-0.40]
mmHg
increase
[0.28-0.58]
mmHg
increase
1.62

HTN

[1.15-1.42]

NA

Lettre G, 2011

BP, SBP, DBP
SBP, DBP, HTN
BP

BP

61

rs12642634

4

LOC105377
468 LOC105377
469
LOC107986
223
LOC107986
335
PRDM8 FGF5

SBP

1.1 mm Hg
increase

harmful

Salvi E, 2017

rs1596724

4

SBP

NA

NA

Taylor JY, 2016

rs11726022

4

SBP

NA

NA

Taylor JY, 2016

rs11099098

4

BP

harmful

Simino J, 2014

4

PRDM8 FGF5

BP, SBP, DBP,
HTN

harmful

rs16998073

4

PRDM8 FGF5

DBP

harmful

Wain LV, 2011; Ehret
GB, 2011; Kato N,
2015
Newton-Cheh C, 2009

rs1902859

4

SBP, DBP, HTN

harmful

Lu X, 2015

rs13107325

4

PRDM8 FGF5
SLC39A8

protective

Wain LV, 2011; Ehret
GB, 2011

rs6825911

4

ZNF969P ENPEP

BP

harmful

Kato N, 2011

rs9313772

5

LOC101927
697

BP

protective

Wain LV, 2011

rs11953630

5

SBP, DBP, HTN

protective

rs13178964

5

protective

Ehret GB, 2011; Kato
N, 2015
He J, 2013

rs1421811

5

LOC101927
697 - EBF1
LOC105379
111 RAB9BP1
NPR3

protective

Simino J, 2014

rs7729447

5

NPR3

BP

harmful

Simino J, 2014

rs1173766

5

NPR3 LOC340113

DBP, SBP

harmful;
protective

Kato N, 2011; Kato N,
2015

rs1173771

5

NPR3 LOC340113

BP, SBP, DBP,
HTN

rs822127

5

DBP

harmful;
harmful;
protective
protective

Wain LV, 2011; Ehret
GB, 2011; Kato N,
2015
Salvi E, 2017

rs13359291

5

PLCXD3 TCP1P2
PRDM6

[0.32-0.72]
mmHg
increase
[0.30-0.51]
mmHg
increase
[0.40-0.60]
mm Hg
increase
[1.07-1.61]
unit increase
[0.44-0.82]
mmHg
decrease
[0.38-0.82]
mm Hg
increase
[0.24-0.44]
mmHg
decrease
0.6 mmHg
decrease
[2.09-4.75]
mmHg
decrease
[0.44-0.94]
mmHg
decrease
[0.26-0.66]
mmHg
increase
[0.41-0.85]
mm Hg
increase
[0.19-0.37]
mmHg
increase
[NR] mmHg
decrease
[0.4-0.66]

rs1458038

harmful

Kato N, 2015

BP, SBP, DBP,
HTN

SBP
BP

SBP

62

rs9687065

5

SH3TC2

DBP

rs6453204

5

SV2C

BP

rs805303

6

BAG6

SBP, DBP, HTN

rs9370524

6

COL21A1

DBP

rs9266359

6

DHFRP2

SBP, DBP

rs1799945

6

HFE

SBP, DBP, HTN

rs6910741

6

BP

rs198846

6

HIST1H2AP
S2 SLC17A2
HIST1H4C HIST1H1T

rs12195230

6

KLHL32

BP

rs16890334

6

BP

rs6924906

6

rs13209747

6

rs2876449

6

rs12195036

6

LOC105377
865 LOC107986
613
LOC105377
871
LOC105377
992 LOC105377
989
LOC105378
027
LOC105378
117

rs675026

6

OPRM1

HTN

rs17080102

6

PLEKHG1

BP

rs11750990

6

SBP

rs7751419

6

rs2021783

6

RNU2-8P SLC25A5P7
SAYSD1 KCNK5
TNXB

BP

BP
BP

SBP
BP

HTN
SBP, DBP, HTN

mmHg
increase
[0.18-0.33]
mmHg
increase
[NR]

harmful

Kato N, 2015

NA

Schneider BP, 2014

[NR] mmHg
increase
[NR] mmHg
increase
[0.24-0.64]
unit increase
[NR] mmHg
increase
[0.36-0.86]
mmHg
decrease
[0.35-0.61]
mmHg
decrease
[1.1-2.48]
mmHg
increase
[1.95-4.45]
mmHg
decrease

harmful

Ehret GB, 2011

harmful

Salvi E, 2017

harmful

Lu X, 2015

harmful

Ehret GB, 2011

protective

Simino J, 2014

protective

Wain LV, 2011

harmful

Simino J, 2014

protective

He J, 2013

[0.31-0.71]
unit decrease
[0.44-1.26]
unit increase

protective

Franceschini N, 2013

harmful

Franceschini N, 2013

[NR] mmHg
decrease
[1.91-4.31]
mmHg
decrease
[1.11-1.3]

protective

Salvi E, 2017

protective

Simino J, 2014

NA

Lettre G, 2011

[0.53-1.51]
unit decrease
[NR] mmHg
increase
unit increase

protective

Franceschini N, 2013

harmful

Salvi E, 2017

harmful

Bis JC, 2015

[0.44-0.92]
unit increase

harmful

Lu X, 2015

63

rs1563788

6

ZNF318

SBP

[0.39-0.63]
mmHg
increase
[1.67-3.95]
mmHg
decrease
[0.31-0.53]
mmHg
decrease

harmful

Kato N, 2015

rs17135875

7

FAM185A,
FBXL13

BP

protective

He J, 2013

rs17477177

7

BP

rs10951933

7

LOC102724
339 RNA5SP23
6
PKD1L1

protective

Wain LV, 2011

[NR] mmHg
increase
[0.73-1.67]
unit increase

harmful

Salvi E, 2017

rs17428471

7

BP

rs7801190

7

RPL35P4 LOC107986
733
SLC12A9

harmful

Franceschini N, 2013

HTN

[1.19-1.44]

NA

Lettre G, 2011

rs12541063

8

LOC101927
845

BP

protective

Kelly TN, 2013

LOC101929
528 UBXN2B
LOC102724
874 LOC105375
911
LOC105375
856

SBP

[0.48-1.14]
mm of
mercury
decrease
[NR] mmHg
decrease

rs2925663

8

protective

Salvi E, 2017

rs13253998

8

SBP

[NR] mmHg
decrease

protective

Salvi E, 2017

rs10504249

8

BP

harmful

He J, 2013

BP

protective

He J, 2013

8

LOC105377
787,
LOC105377
786
MSRA

[2.02-4.42]
mmHg
increase
[1.39-3.19]
mmHg
decrease

rs2627282

8

rs11775334

harmful

Levy D, 2009

rs2071518

8

NOV

BP

harmful

Wain LV, 2011

rs2702888

8

RPL23AP96
- DEFA6

BP

protective

Simino J, 2014

rs2198596

8

SGCZ

DBP

protective

Salvi E, 2017

rs11784910

8

ZDHHC2

SBP, DBP

harmful

Salvi E, 2017

rs3118867

9

DAPK1

BP, HTN

[0.04-0.12]
log odds
increase
[0.21-0.41]
mmHg
increase
[0.83-1.89]
mmHg
decrease
[NR] mmHg
decrease
[NR] mmHg
increase
[0.31-0.67]

protective

Simino J, 2014

DBP

HTN

64

rs4841895

9

LOC100506
532

BP

rs17755650

9

DBP

rs1530440

10

LOC107987
026 - MTAP
C10orf107

rs4590817

10

C10orf107

BP

rs12416687

10

C10orf32ASMT

BP

rs4409766

10

SBP, DBP, HTN

rs11014166

10

C10orf32ASMT,
C10orf32
CACNB2

rs12258967

10

CACNB2

BP

rs11191548

10

CNNM2

BP, SBP, HTN

rs1004467

10

CYP17A1

SBP

rs3824755

10

CYP17A1

BP

rs603788

10

KCNMA1

BP

rs7088591

10

LOC105378
314 MRPS35P3

BP

rs2782980

10

LOC105378
492

BP

rs11191593

10

NT5C2

BP

DBP

SBP, DBP, HTN

mmHg
decrease
[0.5-1.12]
mmHg
increase
[NR] mmHg
increase
[0.27-0.51]
mm Hg
decrease
[0.45-0.71]
mmHg
increase
[0.39-0.79]
mmHg
decrease
[0.95-1.53]
unit increase

harmful

Simino J, 2014

harmful

Salvi E, 2017

protective

Newton-Cheh C, 2009

harmful

Wain LV, 2011

protective

Simino J, 2014

harmful

Lu X, 2015

[0.05-0.13]
log odds
increase
[0.33-0.53]
mmHg
decrease
[0.92-1.40]
mm Hg
increase

harmful

Levy D, 2009

protective

Wain LV, 2011

harmful

[0.74-1.36]
mm Hg
increase
[0.3-0.7] mm
of mercury
decrease
[1.04-2.42]
mmHg
increase
[0.87-2.01]
mm of
mercury
decrease
[0.23-0.45]
mmHg
decrease
[0.50-0.82]
mmHg
increase

harmful

Newton-Cheh C, 2009;
Wain LV, 2011, Ehret
GB, 2011; Kato N,
2011; Kato N, 2015
Levy D, 2009

protective

Kelly TN, 2013

harmful

Simino J, 2014

protective

Kelly TN, 2013

protective

Wain LV, 2011

harmful

Wain LV, 2011; Kelly
TN, 2013

65

rs932764

10

PLCE1

SBP, DBP, HTN

rs9663362

10

PLCE1

BP

rs11816631

10

BP

rs4373814

10

rs11037965

11

rs633185

11

SFRP5 LOC107984
260
SLC39A12 CACNB2
ALX4 LOC105376
645
ARHGAP42

rs7129220

11

CAND1.11

BP, SBP, DBP

rs4601790

11

EHBP1L1

BP

rs1943466

11

GRAMD1B

HTN

rs10832417

11

KCNQ1OT1
, KCNQ1

BP

rs11222084

11

LOC646383

BP

rs2196122

11

OR51H1 OR51H2P

BP

rs11041530

11

OVCH2

BP

rs11024074

11

PLEKHA7

DBP

rs381815

11

PLEKHA7

SBP, HTN

rs1401454

11

SOX6

BP

rs4757391

11

SOX6

SBP, DBP, HTN

rs17249754

12

ATP2B1

BP, SBP, DBP,

SBP, DBP, HTN
BP
BP, SBP, DBP,
HTN

[NR] mmHg
increase
[0.18-0.36]
mmHg
decrease
[1.23-2.75]
mmHg
increase
[NR] mmHg
decrease
[0.83-1.97]
mmHg
decrease
[0.22-0.43]
mmHg
decrease
[0.23-0.53]
mmHg
decrease
[0.012-0.028]
mmHg
decrease per
1 year
increase in
age
[NR]

harmful

Ehret GB, 2011

protective

Wain LV, 2011

harmful

Simino J, 2014

protective

Ehret GB, 2011

protective

He J, 2013

protective;
harmful

Wain LV, 2011; Ehret
GB, 2011; Kato N,
2015
Wain LV, 2011; Ehret
GB, 2011

[0.64-1.46]
mmHg
decrease
[0.24-0.44]
mmHg
increase
[1.17-2.65]
mmHg
increase
[0.86-1.84]
unit decrease
[0.19-0.47]
mm Hg
decrease
[0.43-0.87]
mm Hg
increase
[0.24-0.86]
unit increase
[0.59-1.17]
unit increase
[0.27-0.52]
66

protective
harmful

Simino J, 2014

NA

Schneider BP, 2014

protective

He J, 2013

harmful

Wain LV, 2011

harmful

Simino J, 2014

protective

Franceschini N, 2013

protective

Levy D, 2009

harmful

Levy D, 2009; Wain LV,
2011

harmful

Franceschini N, 2013

harmful

Lu X, 2015

harmful;

Wain LV, 2011; Kato N,

HTN

mmHg
increase

protective

[0.11-0.19]
log odds
increase
[0.60-1.10]
mm Hg
increase
[0.36-0.56]
mm Hg
decrease
[1.31-1.81]
mm Hg
increase
[0.24-0.4]
mmHg
decrease
[0.38-0.88]
mm Hg
increase

harmful

rs2681472

12

ATP2B1

SBP, DBP, HTN

rs2681492

12

ATP2B1

SBP

rs653178

12

ATXN2

BP, SBP, DBP

rs11066280

12

HECTD4

BP, SBP, DBP,
HTN

rs12579720

12

LOC100506
393

DBP

rs35444

12

BP, SBP, DBP

rs11067763

12

rs2384550

12

rs7960884

12

rs4842666

12

LOC102723
639 LOC105370
003
LOC105370
003
LOC107984
437 LOC102723
639
OVOS2 LOC107987
168
POC1B ATP2B1

rs3184504

12

SH2B3

SBP, DBP

rs2315885

13

MIR5007 HNF4GP1

BP

rs8002688

13

PIBF1

BP

rs11158609

14

rs10143078

14

NEDD8,
NEDD8MDP1
SYNJ2BP,

2011; Lu X, 2015; Kelly
TN, 2013; Kato N,
2015
Levy D, 2009; Kato N,
2015

harmful

Levy D, 2009

protective

Newton-Cheh C, 2009;
Wain LV, 2011; Kato N,
2015
Kato N, 2011; Lu X,
2015; Kato N, 2015

harmful
protective

Kato N, 2015

harmful

Kato N, 2011; Lu X,
2015; Kato N, 2015

[0.61-1.01]
unit increase
[0.23-0.47]
mm Hg
decrease

harmful

Lu X, 2015

protective;
harmful

Levy D, 2009; Wain LV,
2011

SBP

[NR] mmHg
increase

harmful

Salvi E, 2017

BP

harmful

Simino J, 2014

harmful
harmful

Levy D, 2009; Ehret
GB, 2011; Kato N,
2015
Kelly TN, 2013

harmful

He J, 2013

SBP

[0.46-0.96]
mmHg
increase
[0.38-0.78]
mm Hg
increase
[0.84-1.98]
mm of
mercury
increase
[1.37-2.71]
mmHg
increase
NA

NA

Taylor JY, 2016

BP

[2.47-5.65]

protective

Simino J, 2014

SBP, DBP, HTN
BP, DBP

67

SYNJ2BPCOX16
TTC6

rs177848

14

DBP

rs6495122

15

CPLX3 ULK3

DBP

rs1378942

15

CSK

BP, SBP, DBP

rs2521501

15

FES

BP, SBP, DBP,
HTN

rs1550576

15

HTN

rs16962897

16

LOC107984
724 ALDH1A2
DNAAF1

rs1862746

16

rs11646213

16

rs2030114

16

rs4150161

16

LOC101927
605
LOC101928
392 CDH13
LOC102723
323 LOC107984
892
TAF1C

rs13333226

16

UMOD

HTN

rs11867410

17

BP

rs11657217

17

APOH RNA5SP44
4
ENPP7

rs17608766

17

GOSR2

BP, SBP

rs16948048

17

LOC102724
596

DBP

rs747685

17

NXN

BP

rs747687

17

NXN

DBP

mmHg
decrease
[NR] mmHg
decrease
[0.28-0.52]
mm Hg
increase
[0.35-0.51]
mm Hg
increase

protective

Salvi E, 2017

harmful

Levy D, 2009

harmful;
protective

[0.22-0.46]
mmHg
increase
[NR]

harmful;
protective
NA

Newton-Cheh C, 2009;
Wain LV, 2011,; Ehret
GB, 2011; Kato N,
2015
Wain LV, 2011; Ehret
GB, 2011; Kato N,
2015
Adeyemo A, 2009

protective

Salvi E, 2017

SBP

[NR] mmHg
decrease
NA

NA

Taylor JY, 2016

HTN

[1.15-1.43]

NA

Org E, 2009

BP

[2.28-4.00]
mmHg
decrease

protective

He J, 2013

SBP

[NR] mmHg
increase
[1.10-1.19]

harmful

Salvi E, 2017

NA

Padmanabhan S, 2010

[2.43-5.49]
mmHg
decrease
[NR] mmHg
decrease
[0.40-0.67]
mmHg
decrease
[0.21-0.41]
mm Hg
increase
[0.91-2.09]
mmHg
increase
[0.86-1.88]
mmHg
increase

protective

He J, 2013

protective

Salvi E, 2017

protective

Wain LV, 2011; Ehret
GB, 2011

harmful

Newton-Cheh C, 2009

harmful

Simino J, 2014

harmful

Simino J, 2014

SBP

DBP

68

rs12946454

17

PLCD3

SBP

harmful

Newton-Cheh C, 2009

SBP

[0.37-0.77]
mm Hg
increase
NA

rs8065772

17

rs8078051

17

PRKCA CACNG5
TTYH2

NA

Taylor JY, 2016

SBP

NA

NA

Taylor JY, 2016

rs12940887

17

ZNF652

BP

harmful

Wain LV, 2011

18

L3MBTL4

HTN

[0.16-0.35]
mmHg
increase
[1.07-1.23]

rs403814

NA

Liu X, 2016

rs1792738

18

SBP

NA

NA

Taylor JY, 2016

rs2217560

18

HTN

[1.59-2.45]

NA

Germain M, 2013

rs1157477

18

LOC105372
132 LOC105372
135
LOC105372
189 CBLN2
LOC339298

SBP

NA

NA

Taylor JY, 2016

rs7233332

18

RAB31

BP

harmful

Simino J, 2014

rs16964543

19

ZNF536

HTN

[0.013-0.033]
mmHg
increase per
1 year
increase in
age
unit decrease

protective

Bis JC, 2015

rs1327235

20

C20orf187

BP, SBP, DBP

harmful;
protective

rs1887320

20

C20orf187

SBP, DBP

harmful

Wain LV, 2011; Ehret
GB, 2011; Kato N,
2015
Lu X, 2015

rs2273359

20

NELFCD

HTN

harmful

Turner ST, 2013

rs16982520

20

ZNF831

HTN

protective

Levy D, 2009

rs6015450

20

ZNF831

BP, SBP, DBP,
HTN

harmful

Wain LV, 2011; Ehret
GB, 2011

rs1735151

21

IGSF5

HTN

[0.17-0.35]
mmHg
increase
[0.51-1.05]
unit increase
[NR] mm Hg
increase
[0.09-0.17]
log odds
decrease
[0.21-0.49]
mmHg
increase
[1.09-1.24]

NA

Lettre G, 2011

rs1475591

21

UBE3AP2 TIAM1

HTN

[1.10-1.27]

NA

Lettre G, 2011

69

rs7286472

22

rs130318

22

LARGE LOC105373
010
PARVB

BP
HTN

[1.39-3.11]
mmHg
decrease
[NR]

protective

He J, 2013

NA

Schneider BP, 2014

SNP: single nucleotide polymorphism identifier based on Human Genome Assembly GRCh37, Chr:
chromosome, SBP: systolic blood pressure, DBP: diastolic blood pressure, HTN: hypertension, [NR]: not
reported, NA: not available
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